Bridge Biotherapeutics, Inc. is a healthcare company founded in 2015 and headquartered in Seongnam, South Korea. It is involved in the discovery and development of novel therapeutics in areas such as ulcerative colitis, fibrotic diseases, and cancers. The company has 11-50 employees and is currently developing BBT-401, a Pellino-1 inhibitor for ulcerative colitis, BBT-877, an autotaxin inhibitor for fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. Bridge Biotherapeutics operates in the Republic of Korea, US, and China and is a publicly-traded clinical-stage biotech company.
Headquarters
303, 58, Pangyo-Ro 258Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do
Seongnam; Gyeonggi;
Contact Details: Purchase the Bridge Biotherapeutics, Inc. report to view the information.
Website: http://www.bridgebiorx.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service